Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

11.88 -0.71 (-5.64%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 18, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	159,772
Open	12.48
Bid (Size)	11.88 (600)
Ask (Size)	11.90 (100)
Prev. Close	12.59
Today's Range	11.70 - 12.48
52wk Range	4.930 - 13.65
Shares Outstanding	33,197,018
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

Today 14:08 EDT

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

Today 13:54 EDT

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

Via The Motley Fool

Performance

YTD	+18.2%	+18.2%
1 Month	+7.8%	+7.8%
3 Month	+4.5%	+4.5%
6 Month	+132.0%	+132.0%
1 Year	+9.9%	+9.9%

More News

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 02, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

February 17, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

February 04, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

January 08, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 04, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Via The Motley Fool

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

Via The Motley Fool

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

Via The Motley Fool

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

November 06, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

October 28, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

September 05, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada (TRDA) Q2 Revenue Drops 98% ↗

August 06, 2025

Via The Motley Fool

Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading ↗

August 06, 2025

Via Chartmill

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

August 06, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 03, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 08, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

March 24, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Entrada Therapeutics, Inc. - Common Stock publicly traded?

Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?

Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?

The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market

What is the current price of Entrada Therapeutics, Inc. - Common Stock?

The current price of Entrada Therapeutics, Inc. - Common Stock is 11.88

When was Entrada Therapeutics, Inc. - Common Stock last traded?

The last trade of Entrada Therapeutics, Inc. - Common Stock was at 03/18/26 04:00 PM ET

What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?

The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 394.38M

How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?

Entrada Therapeutics, Inc. - Common Stock has 394M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.